je.st
news
Home
› Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
Highland Therapeutics Announces Initiation Of Second Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
2015-09-02 07:45:41| drugdiscoveryonline News Articles
Highland Therapeutics Inc. (“Highland”) announced recently that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has dosed the first patient in the second of two pivotal studies of HLD-200
Tags: trial
patients
adhd
announces
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||